annual EBITDA:
-$241.49M-$64.63M(-36.54%)Summary
- As of today (September 17, 2025), NAMS annual EBITDA is -$241.49 million, with the most recent change of -$64.63 million (-36.54%) on December 31, 2024.
- During the last 3 years, NAMS annual EBITDA has fallen by -$200.12 million (-483.74%).
- NAMS annual EBITDA is now -3533.17% below its all-time high of -$6.65 million, reached on December 1, 2020.
Performance
NAMS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$35.59M+$33.28M(+48.33%)Summary
- As of today (September 17, 2025), NAMS quarterly EBITDA is -$35.59 million, with the most recent change of +$33.28 million (+48.33%) on June 30, 2025.
- Over the past year, NAMS quarterly EBITDA has increased by +$16.61 million (+31.81%).
- NAMS quarterly EBITDA is now -27770.01% below its all-time high of -$127.70 thousand, reached on December 1, 2020.
Performance
NAMS quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$171.98M+$16.61M(+8.81%)Summary
- As of today (September 17, 2025), NAMS TTM EBITDA is -$171.98 million, with the most recent change of +$16.61 million (+8.81%) on June 30, 2025.
- Over the past year, NAMS TTM EBITDA has dropped by -$64.84 million (-60.53%).
- NAMS TTM EBITDA is now -134572.67% below its all-time high of -$127.70 thousand, reached on December 1, 2020.
Performance
NAMS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
NAMS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -36.5% | +31.8% | -60.5% |
| 3 y3 years | -483.7% | -1687.7% | -5343.7% |
| 5 y5 years | -3533.2% | -10000.0% | -10000.0% |
NAMS EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -981.0% | at low | -1451.7% | +48.3% | -3283.0% | +8.8% |
| 5 y | 5-year | -3533.2% | at low | <-9999.0% | +48.3% | <-9999.0% | +8.8% |
| alltime | all time | -3533.2% | at low | <-9999.0% | +48.3% | <-9999.0% | +8.8% |
NAMS EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$35.59M(-48.3%) | -$171.98M(-8.8%) |
| Mar 2025 | - | -$68.87M(+59.5%) | -$188.58M(+8.0%) |
| Dec 2024 | -$241.49M(+36.5%) | -$43.18M(+77.4%) | -$174.65M(+32.8%) |
| Sep 2024 | - | -$24.34M(-53.4%) | -$131.47M(+22.7%) |
| Jun 2024 | - | -$52.20M(-5.0%) | -$107.13M(+95.0%) |
| Mar 2024 | - | -$54.94M(+54.7%) | -$54.94M(+38.0%) |
| Dec 2023 | -$176.86M(+691.7%) | - | - |
| Mar 2023 | - | -$35.51M | -$39.80M |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2022 | -$22.34M(-46.0%) | - | - |
| Sep 2022 | - | -$2.29M(+15.2%) | -$5.08M(+60.9%) |
| Jun 2022 | - | -$1.99M(+477.7%) | -$3.16M(+114.4%) |
| Mar 2022 | - | -$344.60K(-24.2%) | -$1.47M(+7.9%) |
| Dec 2021 | -$41.37M(+522.4%) | -$454.60K(+23.1%) | -$1.37M(+31.5%) |
| Sep 2021 | - | -$369.20K(+21.0%) | -$1.04M(+55.1%) |
| Jun 2021 | - | -$305.20K(+28.7%) | -$670.10K(+83.6%) |
| Mar 2021 | - | -$237.20K(+85.7%) | -$364.90K(+185.7%) |
| Dec 2020 | -$6.65M | -$127.70K | -$127.70K |
FAQ
- What is NewAmsterdam Pharma Company N.V. annual EBITDA?
- What is the all time high annual EBITDA for NewAmsterdam Pharma Company N.V.?
- What is NewAmsterdam Pharma Company N.V. annual EBITDA year-on-year change?
- What is NewAmsterdam Pharma Company N.V. quarterly EBITDA?
- What is the all time high quarterly EBITDA for NewAmsterdam Pharma Company N.V.?
- What is NewAmsterdam Pharma Company N.V. quarterly EBITDA year-on-year change?
- What is NewAmsterdam Pharma Company N.V. TTM EBITDA?
- What is the all time high TTM EBITDA for NewAmsterdam Pharma Company N.V.?
- What is NewAmsterdam Pharma Company N.V. TTM EBITDA year-on-year change?
What is NewAmsterdam Pharma Company N.V. annual EBITDA?
The current annual EBITDA of NAMS is -$241.49M
What is the all time high annual EBITDA for NewAmsterdam Pharma Company N.V.?
NewAmsterdam Pharma Company N.V. all-time high annual EBITDA is -$6.65M
What is NewAmsterdam Pharma Company N.V. annual EBITDA year-on-year change?
Over the past year, NAMS annual EBITDA has changed by -$64.63M (-36.54%)
What is NewAmsterdam Pharma Company N.V. quarterly EBITDA?
The current quarterly EBITDA of NAMS is -$35.59M
What is the all time high quarterly EBITDA for NewAmsterdam Pharma Company N.V.?
NewAmsterdam Pharma Company N.V. all-time high quarterly EBITDA is -$127.70K
What is NewAmsterdam Pharma Company N.V. quarterly EBITDA year-on-year change?
Over the past year, NAMS quarterly EBITDA has changed by +$16.61M (+31.81%)
What is NewAmsterdam Pharma Company N.V. TTM EBITDA?
The current TTM EBITDA of NAMS is -$171.98M
What is the all time high TTM EBITDA for NewAmsterdam Pharma Company N.V.?
NewAmsterdam Pharma Company N.V. all-time high TTM EBITDA is -$127.70K
What is NewAmsterdam Pharma Company N.V. TTM EBITDA year-on-year change?
Over the past year, NAMS TTM EBITDA has changed by -$64.84M (-60.53%)